(Q35970489)

English

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert Peter Gale

7

object named as

Robert Peter Gale

1 reference

Europe PubMed Central

11 August 2017

PMC publication ID

12

object named as

Joseph Antin

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Stephen Spellman

10

object named as

Stephen Spellman

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Steven Z. Pavletic

18

object named as

Steven Pavletic

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Voravit Ratanatharathorn

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Brent Logan

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dan Wang

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Mary Horowitz

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Joseph P Uberti

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Olle Ringden

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hanna Khoury

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Mukta Arora

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Corey Cutler

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Martin Bornhaüser

13

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Gregory Hale

14

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Leo Verdonck

15

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Mitchell Cairo

16

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Vikas Gupta

17

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

19

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

26 March 2009

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

145

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

816-824

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Rituximab for steroid-refractory chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Chronic graft-versus-host disease: clinical manifestation and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

2 October 2017

B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

11 July 2018

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

11 July 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

11 July 2018

The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

11 July 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

24 September 2018

Quantification of the completeness of follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

24 September 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

24 September 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

24 September 2018

The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

24 September 2018

Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3355660

14 November 2018

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical status and optimal use of rituximab for B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19344418

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2009.07674.X

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35970489&oldid=1954544215"